1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Arenavirus Infection Lassa Fever - Pipeline Review, H1 2015

Arenavirus Infection Lassa Fever - Pipeline Review, H1 2015

  • February 2015
  • -
  • Global Markets Direct
  • -
  • 33 pages

Arenavirus Infection Lassa Fever - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Arenavirus Infection Lassa Fever - Pipeline Review, H1 2015’, provides an overview of the Arenavirus Infection Lassa Fever’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Arenavirus Infection Lassa Fever, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Arenavirus Infection Lassa Fever and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Arenavirus Infection Lassa Fever
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Arenavirus Infection Lassa Fever and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Arenavirus Infection Lassa Fever products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Arenavirus Infection Lassa Fever pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Arenavirus Infection Lassa Fever
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Arenavirus Infection Lassa Fever pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Arenavirus Infection Lassa Fever - Pipeline Review, H1 2015
Table of Contents
Introduction 5
Global Markets Direct Report Coverage 5
Arenavirus Infection Lassa Fever Overview 6
Therapeutics Development 7
Pipeline Products for Arenavirus Infection Lassa Fever - Overview 7
Pipeline Products for Arenavirus Infection Lassa Fever - Comparative Analysis 8
Arenavirus Infection Lassa Fever - Therapeutics under Development by Companies 9
Arenavirus Infection Lassa Fever - Therapeutics under Investigation by Universities/Institutes 10
Arenavirus Infection Lassa Fever - Pipeline Products Glance 11
Early Stage Products 11
Arenavirus Infection Lassa Fever - Products under Development by Companies 12
Arenavirus Infection Lassa Fever - Products under Investigation by Universities/Institutes 13
Arenavirus Infection Lassa Fever - Companies Involved in Therapeutics Development 14
Profectus BioSciences, Inc. 14
SIGA Technologies, Inc. 15
Arenavirus Infection Lassa Fever - Therapeutics Assessment 16
Assessment by Monotherapy Products 16
Assessment by Target 17
Assessment by Mechanism of Action 18
Assessment by Molecule Type 19
Drug Profiles 21
EMER-IT - Drug Profile 21
Product Description 21
Mechanism of Action 21
RandD Progress 21
lassa fever vaccine - Drug Profile 22
Product Description 22
Mechanism of Action 22
RandD Progress 22
lassa fever vaccine 1 - Drug Profile 23
Product Description 23
Mechanism of Action 23
RandD Progress 23
lassa fever vaccine 2 - Drug Profile 24
Product Description 24
Mechanism of Action 24
RandD Progress 24
Monoclonal Antibodies for Viral Infections - Drug Profile 25
Product Description 25
Mechanism of Action 25
RandD Progress 25
Small Molecules to Inhibit NPC1 for Ebola and Lassa Fever Virus - Drug Profile 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
ST-161 - Drug Profile 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
ST-193 - Drug Profile 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
Arenavirus Infection Lassa Fever - Recent Pipeline Updates 30
Arenavirus Infection Lassa Fever - Dormant Projects 31
Appendix 32
Methodology 32
Coverage 32
Secondary Research 32
Primary Research 32
Expert Panel Validation 32
Contact Us 32
Disclaimer 33

List of Tables

Number of Products under Development for Arenavirus Infection Lassa Fever, H1 2015 7
Number of Products under Development for Arenavirus Infection Lassa Fever - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Number of Products under Investigation by Universities/Institutes, H1 2015 10
Comparative Analysis by Early Stage Development, H1 2015 11
Products under Development by Companies, H1 2015 12
Products under Investigation by Universities/Institutes, H1 2015 13
Arenavirus Infection Lassa Fever - Pipeline by Profectus BioSciences, Inc., H1 2015 14
Arenavirus Infection Lassa Fever - Pipeline by SIGA Technologies, Inc., H1 2015 15
Assessment by Monotherapy Products, H1 2015 16
Number of Products by Stage and Target, H1 2015 17
Number of Products by Stage and Mechanism of Action, H1 2015 18
Number of Products by Stage and Molecule Type, H1 2015 20
Arenavirus Infection Lassa Fever Therapeutics - Recent Pipeline Updates, H1 2015 30
Arenavirus Infection Lassa Fever - Dormant Projects, H1 2015 31

List of Figures

Number of Products under Development for Arenavirus Infection Lassa Fever, H1 2015 7
Number of Products under Development for Arenavirus Infection Lassa Fever - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Number of Products under Investigation by Universities/Institutes, H1 2015 10
Comparative Analysis by Early Stage Products, H1 2015 11
Assessment by Monotherapy Products, H1 2015 16
Number of Products by Stage and Top 10 Targets, H1 2015 17
Number of Products by Top 10 Molecule Types, H1 2015 19
Number of Products by Stage and Top 10 Molecule Types, H1 2015 19

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
2016 Virology and Bacteriology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales and Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

2016 Virology and Bacteriology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales and Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

  • $ 54501
  • Industry report
  • October 2016
  • by Venture Planning Group

This unique 33-country survey from VPGMarketResearch.com contains over 2,100 pages, 875 tables and provides data and analysis not available from any other published source. The survey is designed to assist ...

2016 Infectious Disease Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

2016 Infectious Disease Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

  • $ 54501
  • Industry report
  • October 2016
  • by Venture Planning Group

This unique 33-country survey from VPGMarketResearch.com contains over 2,100 pages, 875 tables and provides data and analysis not available from any other published source. The survey is designed to assist ...

2016 Microbiology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Molecular Diagnostic, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, and Immunodiagnostic Tests

2016 Microbiology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Molecular Diagnostic, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, and Immunodiagnostic Tests

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,000 pages and 550 tables, and provides granular data and analysis not available from any other published source. The survey is designed ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.